This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ATTENTION SHAREHOLDERS: Obagi Medical Products, Inc. (OMPI) Board Of Directors Investigated By The Young Law Firm For Possible Breaches Of Fiduciary Duty

The Young Law Firm is investigating potential claims against the Board of Directors of Obagi Medical Products, Inc. (“Obagi Medical” or the “Company”) (NasdaqGS: OMPI) concerning the proposed buyout of the Company by Valeant Pharmaceuticals International, Inc. The investigation concerns whether Obagi Medical‘s Board of Directors obtained fair value for the sale of the Company and whether the Board has fulfilled its fiduciary duties to Obagi Medical‘s shareholders in connection with the sale.

Under the terms of the transaction, shareholders will receive $19.75 for each share of Obagi common stock they own.

Shareholders have rights. If you own shares of Obagi Medical and would like to learn more about these matters, please contact:

Henry Young Esq. The Young Law Firm Toll Free: (888) 452-7252 Email: contact@theyounglf.com or visit: www.theyounglf.com/obagi-medical-merger-buyout-shareholder-lawsuit/

The Young Law Firm is a national shareholder litigation firm located outside of Philadelphia, Pa. We protect individual and institutional investors in state and federal courts nationwide. For more information about the firm and class action cases in general, please visit our website: www.theyounglf.com.

Legal Notice: Pursuant to the laws of certain states of the United States this press release may be considered attorney advertising. That The Young Law Firm may have recovered money and other benefits for shareholders in the past does not mean they will do so again. Past performance does not guarantee future results. We are further obliged to tell you that The Young Law Firm may divide legal fees with other law firms and / or seek referral fees in connection with the content of this message.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs